NASDAQ:TBIO
Delisted
Translate Bio, Inc. Stock News
$37.36
+0 (+0%)
At Close: Aug 17, 2022
Telesis Bio to Present at Antibody Engineering and Therapeutics, Europe 2023
03:00am, Tuesday, 06'th Jun 2023
Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery
Telesis Bio to Present at SynBioBeta 2023
09:00am, Tuesday, 23'rd May 2023
Highlighting application of the Molecular Biology Workstation to accelerating vaccine and biologics discovery Highlighting application of the Molecular Biology Workstation to accelerating vaccine and
Telesis Bio to Present at Protein Engineering Summit (PEGS Boston 2023)
09:00am, Monday, 15'th May 2023
Showcasing Automated Molecular Biology Workstation for Synthetic Biology and Genomics Applications Showcasing Automated Molecular Biology Workstation for Synthetic Biology and Genomics Applications
Telesis Bio (TBIO) Reports Q1 Loss, Misses Revenue Estimates
07:02pm, Thursday, 11'th May 2023
Telesis Bio (TBIO) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.45 per share a year ago.
Telesis Bio to Report First Quarter Financial Results on Thursday, May 11, 2023
04:05pm, Thursday, 27'th Apr 2023
SAN DIEGO, April 27, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its first quarter 2023
Telesis Bio, Inc. (TBIO) Q4 2022 Earnings Call Transcript
10:28am, Saturday, 25'th Mar 2023
Telesis Bio, Inc. (NASDAQ:TBIO ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Jen Carroll - VP, IR Todd Nelson - President, CEO & Director Eric Esser - COO Conferenc
Telesis Bio (TBIO) Reports Q4 Loss, Tops Revenue Estimates
07:04pm, Tuesday, 21'st Mar 2023
Telesis Bio (TBIO) delivered earnings and revenue surprises of 12.50% and 5.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Telesis Bio to Present at Festival of Biologics Conference
06:00am, Thursday, 16'th Mar 2023
Daniel Gibson, Ph.D., CTO and Co-founder to Present “Building Biology Overnight: Eliminating Synthesis Bottlenecks with Hands-free Automated Synthetic Biology Solutions” Daniel Gibson, Ph.D., CTO
Should You Buy Telesis Bio (TBIO) After Golden Cross?
11:27am, Tuesday, 14'th Mar 2023
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Telesis Bio to Present at RNA Leaders Europe Congress
06:00am, Tuesday, 14'th Mar 2023
Showcasing Benchtop Automation for mRNA Synthesis beginning from Sequence or Plasmid DNA Showcasing Benchtop Automation for mRNA Synthesis beginning from Sequence or Plasmid DNA
Telesis Bio to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 21, 2023
04:30pm, Thursday, 09'th Mar 2023
SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its fourth quarter and
Telesis Bio to Present at the Cowen 43rd Annual Healthcare Conference
09:00am, Monday, 27'th Feb 2023
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that Todd R. Nelson, PhD, the company's
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 08'th Sep 2021
LEXINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medic
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Translate Bio, Inc. - TBIO
08:35pm, Monday, 16'th Aug 2021
NEW YORK, Aug. 16, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Ac
Inside Sanofi's $3.2B Translate Bio Buyout
04:19pm, Monday, 16'th Aug 2021
Before the $3.2 billion acquisition of mRNA player Translate Bio Inc (NASDAQ: TBIO) earlier this month, Sanofi SA (NASDAQ: SNY) expressed interest in selling off around 25% of its shares in the
